Pharmaceuticals & Therapeutics

A $15.97M federal grant will help Virginia's APM Tech Hub create a fully domestic drug supply chain, tackling critical shortages and boosting US manufacturing.

As its lead therapy for NCFB enters clinical trials, Revagenix promotes a seasoned drug developer to steer its patient-centric strategy in the chronic disease market.

As Qlosi refill rates hit 49%, Orasis shuns telehealth trends, investing in programs that put eye care professionals back at the center of care.

Verrica Pharma's deal with Medomie brings YCANTH®, a novel skin treatment, to Israel, highlighting a strategy that blends global growth with public health.

PolyPid inks a transformative partnership with Azurity for its surgical infection drug, D-PLEX100, securing over $320M and a clear path to market.

Jupiter Neurosciences' $100M deal for a novel MDMA drug signals a major strategic shift, betting on a new era of psychedelic medicine in the U.S.

Avaí Bio's new deal for its Insulinova therapy brings a mysterious, world-class partner to the table, signaling a major step toward a functional cure for diabetes.

An upcoming FDA meeting on peptide compounding is more than a regulatory footnote. It's a battleground for the future of personalized and preventive care.

At AIDS 2026, ViiV Healthcare unveils data challenging treatment norms, proving long-acting injectable efficacy, and paving the way for quarterly PrEP.

Berlin-based OMEICOS gets a major FDA boost, advancing its novel PMD drug OMT-28 directly to a pivotal Phase 3 trial. A deep dive into the science.

With a new CFO known for turnarounds and a new leader for its clinic network, Neuronetics is making a strategic bet on financial discipline and patient care.

New research reveals how IntraBio's AQNEURSA recalibrates cellular function, a novel mechanism that could revolutionize treatment for a wide range of diseases.

A Rwandan-owned company reports promising results for a long-acting TB drug. It could transform treatment, but it also signals a shift in global health innovation.

A new study validates Actinogen's cortisol-inhibiting drug for depression, creating a strategic tailwind for its primary Alzheimer's program due in November.

Dogwood Therapeutics hits a critical trial milestone for its non-opioid pain drug, signaling a potential breakthrough for millions of cancer survivors.

Lundbeck completes enrollment for a pivotal trial testing a novel drug for severe childhood epilepsies. But what are the real stakes for patients and investors?

Kibow Biotech's AANP award for its kidney health probiotics isn't just a win for the company; it's a major nod to the growing role of the gut-kidney axis.

Arch Biopartners is fast-tracking a novel therapy for diabetic kidney disease, targeting IL-32 to address a massive unmet medical need for millions globally.

Neurizon Therapeutics completes enrollment for its NUZ-001 ALS trial at record speed, accelerating the timeline for potential new treatment data to 2027.

Curative Biotechnology secures a key U.S. patent for a metformin eye-drop, a novel approach that could transform treatment for macular degeneration.